RLAY

Relay Therapeutics Inc. (RLAY) | Rumor.io

Relay Therapeutics

RLAY

Attention (50-day avg)0%

Attention rank (50-day avg)#1,476

Bullish sentiment (50-day avg)100%

Price to earnings ratio-11

Market capitalization3.9B

Earnings per share-1.56

Dividend yield (TTM)—

Revenue (annual)15.4M

Net income (annual)-276.5M

Social

What share of all stock conversation is about RLAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 17

The author notes that $RLAY has been "melting up under the radar" and expects the move to continue, citing volume profiles as an indicator.
The company's stock is identified as a potential candidate for a specific trading setup, referred to as "Qullamaggie."
The author is seeking feedback from others on the chart of $RLAY, indicating it as a point of discussion.

Generated by AI

Sentiment

Of the messages about RLAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +6	94.12% +25.14
Bearish	—	—	0% -6	5.88% -25.14

Bullish· May 19

The community has identified Relay Therapeutics as a potential gem, with one member starting a position at $13.22.
The company's stock price has been influenced by institutional buying, with one member predicting it could rise to $150/share.
The biotech sector is volatile and exciting, with one member describing it as "crazy".

Bearish· Sep 9

The market is overbought, which could lead to a pullback or decline in $RLAY.
The company's stock dilution to under $7 is a concern, making it a less attractive investment opportunity.
The recent trial result news and subsequent price action may be indicative of a pre-arranged offering, which could negatively impact the stock's value.

Generated by AI

Topics

Of the messages about RLAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	92.59%	80.7%	69.74%
Technical Analysis	0%	7.41%	3.51%	12.08%
Analysts	0%	0%	15.79%	9.05%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.75%
Macro	0%	0%	0%	8.39%

May 19

Relay Therapeutics announces initial clinical data demonstrating that zovegalisib has potential for differentiated safety and efficacy in patients with PIK3CA-driven vascular anomalies, with a 60% volumetric response rate across doses and 89% of patients showing clinical improvement.
The company launches an underwritten public offering of $175M of common stock, with underwriters having a 30-day option to purchase up to an additional 15% of the offered shares.
Initial Phase 2 ReInspire data for zovegalisib in PIK3CA-driven vascular anomalies showed a manageable safety profile, with zero discontinuations due to adverse events, and promising efficacy, with 60% of patients achieving a volumetric response at the earliest time point.

Generated by AI

Community

Of the messages about RLAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	37.5%	71.11%	75%	39.57%
Newcomers	62.5%	28.89%	25%	60.43%

Regulars· May 19

The initial Phase 2 data for zovegalisib in patients with PIK3CA-driven vascular anomalies showed a manageable safety profile and a meaningful lesion shrinkage.
The volumetric response rate for zovegalisib is 60%, and the median progression-free survival in Phase 3 breast cancer is 11.1 months.
Relay Therapeutics announced plans to raise $175 million through an underwritten public offering of common stock, which led to a decline in the stock price.

Newcomers· May 20

The company's Phase 2 data and potential for a rare disease treatment with minimal competition could be a major catalyst, despite recent dilutive offerings and retail panic.
A financial model analysis projects Zovegalisib's future cash flows, concluding a risk-adjusted net present value (NPV) of $1.17 billion, suggesting a potential blockbuster drug.
The stock is experiencing significant price movements, with a 7.4% pre-market gap and a 10.6% intraday increase, on above-average trading volume.

Generated by AI

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical library (DEL) screen. Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, licensed an inhibitor of the oncology target phosphoinositide 3- kinase alpha (Pl3K

7d agoYahoo Finance

Relay Therapeutics at Morgan Stanley conference: multiple shots on goal

13d agoInvesting.com

Relay Therapeutics R&D president sells $161,814 in stock

20d agoInvesting.com

Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing

Sanjiv Patel, Director, President, and CEO, on September 08, 2026, sold 48,199 shares in Relay Thera

21d agoYahoo Finance

Relay Therapeutics at Wells Fargo conference: pipeline nears key tests

21d agoInvesting.com

Relay Therapeutics CFO Sells 17,717 Shares for $350,000 | The Motley Fool

Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.

27d agoThe Motley Fool

Also Discussed

Investors talking about RLAY also mention

#	Name	Attention
1	Arcus Biosciences, Inc.RCUS	0%new
2	Tango Therapeutics Inc.TNGX	0%new
3	Kymera Therapeutics Inc.KYMR	0%0
4	Nurix Therapeutics, Inc.NRIX	0%new
5	Kulicke & Soffa Industries, Inc.KLIC	0%0
6	Cullinan Therapeutics Inc.CGEM	0%new
7	EXAI - Exscientia plc	——
8	Cohu, Inc.COHU	0.02%+0
9	Xometry Inc.XMTR	0%new
10	Spyre Therapeutics, Inc.SYRE	0%new

Relay Therapeutics Inc.

Healthcare
Biotechnology

Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods. Its current pipeline centers on targeted cancer programs, including candidates for genetically defined tumors, as well as selected genetic disease applications. Relay Therapeutics Inc. operates in the biopharmaceutical sector with a strong emphasis on precision oncology, where it aims to design more selective therapies for molecularly characterized diseases. Based in Cambridge, Massachusetts, the company works at the intersection of drug discovery technology and clinical development, making it a notable participant in the small-molecule precision medicine market.

Website

Location

60 Hampshire Street

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about RLAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 17

The author notes that $RLAY has been "melting up under the radar" and expects the move to continue, citing volume profiles as an indicator.
The company's stock is identified as a potential candidate for a specific trading setup, referred to as "Qullamaggie."
The author is seeking feedback from others on the chart of $RLAY, indicating it as a point of discussion.

Generated by AI

Sentiment

Of the messages about RLAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +6	94.12% +25.14
Bearish	—	—	0% -6	5.88% -25.14

Bullish· May 19

The community has identified Relay Therapeutics as a potential gem, with one member starting a position at $13.22.
The company's stock price has been influenced by institutional buying, with one member predicting it could rise to $150/share.
The biotech sector is volatile and exciting, with one member describing it as "crazy".

Bearish· Sep 9

The market is overbought, which could lead to a pullback or decline in $RLAY.
The company's stock dilution to under $7 is a concern, making it a less attractive investment opportunity.
The recent trial result news and subsequent price action may be indicative of a pre-arranged offering, which could negatively impact the stock's value.

Generated by AI

Topics

Of the messages about RLAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	92.59%	80.7%	69.74%
Technical Analysis	0%	7.41%	3.51%	12.08%
Analysts	0%	0%	15.79%	9.05%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.75%
Macro	0%	0%	0%	8.39%

May 19

Relay Therapeutics announces initial clinical data demonstrating that zovegalisib has potential for differentiated safety and efficacy in patients with PIK3CA-driven vascular anomalies, with a 60% volumetric response rate across doses and 89% of patients showing clinical improvement.
The company launches an underwritten public offering of $175M of common stock, with underwriters having a 30-day option to purchase up to an additional 15% of the offered shares.
Initial Phase 2 ReInspire data for zovegalisib in PIK3CA-driven vascular anomalies showed a manageable safety profile, with zero discontinuations due to adverse events, and promising efficacy, with 60% of patients achieving a volumetric response at the earliest time point.

Generated by AI

Community

Of the messages about RLAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	37.5%	71.11%	75%	39.57%
Newcomers	62.5%	28.89%	25%	60.43%

Regulars· May 19

The initial Phase 2 data for zovegalisib in patients with PIK3CA-driven vascular anomalies showed a manageable safety profile and a meaningful lesion shrinkage.
The volumetric response rate for zovegalisib is 60%, and the median progression-free survival in Phase 3 breast cancer is 11.1 months.
Relay Therapeutics announced plans to raise $175 million through an underwritten public offering of common stock, which led to a decline in the stock price.

Newcomers· May 20

The company's Phase 2 data and potential for a rare disease treatment with minimal competition could be a major catalyst, despite recent dilutive offerings and retail panic.
A financial model analysis projects Zovegalisib's future cash flows, concluding a risk-adjusted net present value (NPV) of $1.17 billion, suggesting a potential blockbuster drug.
The stock is experiencing significant price movements, with a 7.4% pre-market gap and a 10.6% intraday increase, on above-average trading volume.

Generated by AI

Relay Therapeutics

Social

Aug 17

Sentiment

Bullish· May 19

Bearish· Sep 9

Topics

May 19

Community

Regulars· May 19

Newcomers· May 20

News

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

Relay Therapeutics at Morgan Stanley conference: multiple shots on goal

Relay Therapeutics R&D president sells $161,814 in stock

Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing

Relay Therapeutics at Wells Fargo conference: pipeline nears key tests

Relay Therapeutics CFO Sells 17,717 Shares for $350,000 | The Motley Fool

Also Discussed

Relay Therapeutics Inc.

Company Information

Location

News

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

Relay Therapeutics at Morgan Stanley conference: multiple shots on goal

Relay Therapeutics R&D president sells $161,814 in stock

Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing

Relay Therapeutics at Wells Fargo conference: pipeline nears key tests

Relay Therapeutics CFO Sells 17,717 Shares for $350,000 | The Motley Fool

Also Discussed

Social

Aug 17

Sentiment

Bullish· May 19

Bearish· Sep 9

Topics

May 19

Community

Regulars· May 19

Newcomers· May 20